Prostate Disorders News

600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical ... - Reuters



600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical ... 
Reuters
In a crowded prostate cancer space, we also recognize the quality and diligence of the work of our partner Active Biotech to bring new therapies to patients." Marc de Garidel added: "Ipsen is now in the final stage of designing the randomized ...

and more » 


Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data ... - Reuters



Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data ... 
Reuters
The presentation will provide overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC). The poster "Tasquinimod and survival in men with metastatic castration-resistant ...

and more » 


Higher Hospital Volume More Important Than Surgeon Experience in Outcome of ... - Midland Daily News



Higher Hospital Volume More Important Than Surgeon Experience in Outcome of ... 
Midland Daily News
Older, sicker, high-risk patients who undergo one of the most common treatments for prostate cancer get better results in larger, busier hospitals, according to new research by Henry Ford Hospital. In such cases, the same research showed the experience ...

and more » 


Ask the Experts: Prostate problems - WalesOnline



Ask the Experts: Prostate problems 
WalesOnline
It's ironic then, that when it comes to other health conditions such as prostate disorders, men tend not to talk about them. Although only the size of a walnut, the prostate gland is prone to some distressing problems. One of these is benign prostatic ...

and more » 


Myriad Genetics' CEO Presents at Bank of America Merrill Lynch Health Care ... - Seeking Alpha



Myriad Genetics' CEO Presents at Bank of America Merrill Lynch Health Care ... 
Seeking Alpha
And we have prognostic medicine products like Prolaris that can assess how aggressive a man's prostate cancer is likely to be, because most men have a slow-growing, indolent form of the disease that don't require aggressive therapy, and there are too ...

and more » 


With Biotechs Back In Limelight, OPKO's Alzheimer's Diagnostic And Other ... - Forbes



With Biotechs Back In Limelight, OPKO's Alzheimer's Diagnostic And Other ... 
Forbes
Among its major drugs currently undergoing clinical studies is a blood-based diagnostic test for Alzheimer's disease. It has also developed its own diagnostic screening system for prostate cancer, which is scheduled to be launched in Europe sometime ...

 


Cancer Experts Detail Treatments using TrueBeam System to Reduce Number of ... - MarketWatch (press release)



Cancer Experts Detail Treatments using TrueBeam System to Reduce Number of ... 
MarketWatch (press release)
Dr. Filippo Alongi, radiation oncologist at Humanitas Cancer Center in Rozzano-Milan, reported that he has used hypo-fractionation to reduce the number of treatment sessions for prostate cancer from 30 to as few as five. The center is equipped with ...

and more » 


Erbe: It's time to stop foot-dragging on BPA ban - The Times Herald



Erbe: It's time to stop foot-dragging on BPA ban 
The Times Herald
The list of diseases and disorders now scientifically connected to BPA is lengthy and scary. Many are considered to be at epidemic proportions, even though we have yet to find cures. They include obesity, infertility, early puberty, prostate disease, ...

 


NICE gives final rejection to Sanofi's Jevtana for prostate cancer - PMLiVE



NICE gives final rejection to Sanofi's Jevtana for prostate cancer 
PMLiVE
In its final guidance NICE sticks to its verdict that the drug is not suitable for NHS reimbursement at its current median cost of £22200 per patient as a second line treatment for prostate cancer in combination with prednisone or prednisolone.

and more » 


This machine can defer prostate surgery for years. Yet worryingly few British ... - Daily Mail



Daily Mail 
This machine can defer prostate surgery for years. Yet worryingly few British ... 
Daily Mail
By Jane Feinmann Many men will have been left shaken by the news this week that operations to treat prostate cancer are little more effective in saving lives than 'watchful waiting'. This will have be particularly difficult news because the surgery ...

and more »